RBC downgrades Moderna and cuts price target by 28%: Should you exit?
The decision by RBC Capital Markets to downgrade Moderna Inc. (NASDAQ: MRNA) from “Outperform” to “Sector Perform” has sent the stock tumbling by over 6% in pre-market trading on Monday. This downgrade reflects growing concerns about Moderna’s near-term prospects amid an increasingly challenging market for its flagship COVID-19 and RSV vaccines. Alongside the downgrade, RBC